PolyNovo Limited (PNV) Earnings Call Transcript & Summary
August 26, 2026
Earnings Call Speaker Segments
Operator
operatorWe appreciate everyone being on the line, and we're glad to have you join us for PolyNovo's FY '26 results. <<operator_script>> At this point, I'll turn the call over to Bruce Peatey, our Chief Executive Officer. Bruce, the floor is yours.
Bruce Peatey
executiveGood morning, everyone, and welcome — thank you for being with us. Since I joined PolyNovo back in December, I've had the chance to spend time with customers, clinicians, employees and shareholders across the globe, and I've also been going through the business in detail. My assessment, and I'm confident in it, is that PolyNovo is becoming a stronger and more capable business, with a sustainable runway of potential for us to capture. As we look ahead, FY '27 is less about building capability and more about converting that capability into outcomes, reliable performance, broader adoption of the portfolio and milestone completion, which leads to stronger returns and long-term shareholder value. With that context in mind, I'll share some key highlights from FY '26, the opportunity ahead and our key priorities for FY '27, and then I'll hand over to Jan to review the FY '26 financial results. If we go to the next slide. Here we have the standard disclaimers. Move to the next slide. So PolyNovo's origins are centered around large complex burns. The way NovoSorb BTM uniquely and specifically addresses the care needs of critically ill burns patients, giving surgeons the time and control they need to address these complex cases, has really truly redefined what is possible in this category.
Bruce Peatey
executiveWhat we're increasingly seeing is NovoSorb BTM, and now MTX, being used in trauma, reconstruction, limb salvage and other complex wounds, which reflects how versatile the NovoSorb portfolio is. As a growing number of surgeons witness positive outcomes in new procedures involving our products, the growth potential gets stronger. Taken together, these markets represent an estimated total available market of more than $2 billion. Let me be clear: BTM in large burns established PolyNovo's clinical credibility and will stay an important growth lever going forward. However, NovoSorb's opportunity is far broader. That is significant because PolyNovo is fundamentally a platform company, with a substantial complex wounds business today and wider potential over time. Including these images today mattered to me. The lives of patients around the world that our technology positively impacts are a daily source of inspiration and pride for our whole team. So, the next slide. In FY '26, we sharpened our focus on strengthening our foundations, while commercial momentum carried on, with more cases covered than ever before across more types of procedures, in more hospitals and countries worldwide. The clinical study report for the U.S. pivotal RCT has now been finalized, which marks an important milestone for PolyNovo.
Bruce Peatey
executiveWe’ve now finished one of the biggest and most rigorous burn studies carried out in decades. We’re eager to keep investors informed about the trial results as we move ahead through the coming phases of regulatory review and commercialization. We’re also glad to report that BTM obtained regulatory clearance in 8 more markets. MTX kept up its commercial rollout, posting nearly 90% year-on-year growth in FY ’26. We anticipate that momentum will carry on as clinical evidence and clinician experience keep expanding. Construction of the new manufacturing facility is finished, with transition plans now in progress, and our leadership team grew stronger through proven capabilities across science, quality, IP and governance. We’ve also put investment into critical strategic marketing and market access capabilities to actively propel the next wave of growth. Every one of these elements will leave us better able to scale the organization and drive the financial growth trajectory. Next slide. Here I’ll share some of the financial highlights. FY ’26 kept delivering growth, with group, U.S. and rest-of-world sales each rising more than 21% in constant currency. We’ve added constant currency detail in response to the volatile forex landscape over the prior year and to offer a more accurate reflection of local market momentum.
Bruce Peatey
executiveWhat matters is that EBITDA rose sharply compared with the prior year, even as we keep putting money into the infrastructure and capabilities I mentioned earlier. Operating cash flow improved in a way that matches what we told you to expect in the first half earnings update, and we're quite happy about that — free cash flow for the year came to $9.4 million. Jan will walk you through the financial performance and the main drivers in more detail in a moment. So, on to the next slide. I know some of you may have questions about how growth in the United States is trending in the second half of FY '26, so let's tackle that now. This chart shows the sales growth trend across recent years in the U.S., setting revenue from large burn procedures against all other procedures. Large burn cases are lumpy by nature. Large burn cases come up infrequently and vary in size, which can swing sales variances more than other typical market forces do. A good example: we had strong growth in large burn cases in the first half of FY '26 following a stretch of weaker growth. Fewer of those large cases came through in the second half of 2026. At the same time, our deliberate push into procedures beyond large burns, including the launch of MTX, is paying off, with a 52.8% 3-year CAGR driven by a growing number of complex wound applications.
Bruce Peatey
executiveThis matters because complicated wounds aren't just some future opportunity. They're already a growth engine that's becoming increasingly significant. Closing FY '26 with a record U.S. sales month in June gives us confidence that this business isn't running out of opportunity. It does suggest our growth drivers are rightly shifting, widening, and maturing. And I'm happy to share that we began FY '27 by carrying forward the FY '26 momentum, with a group sales record for July. Next slide. MTX is a good illustration of how we can leverage the NovoSorb platform into new clinical applications and create meaningful commercial traction. In FY '26, sales rose to $12.6 million from $6.7 million the year before, with MTX now commercially available across 6 markets, and the regulatory pathway for the U.K. is well underway. What's most encouraging is what our clinicians tell us about the positive outcomes they're seeing with MTX, whether used stand-alone or increasingly in combination with BTM. We've shared a few of those comments here on the right. MTX's versatility in combination with the NovoSorb credibility gained from BTM is enabling use across a broad range of reconstructive and complex wound challenges, which supports our confidence in the opportunity for further adoption.
Bruce Peatey
executiveMoving to the next slide, the amount of evidence backing wider use of the NovoSorb portfolio across a broader set of clinical applications keeps expanding, and that confirms how credible NovoSorb technology is. We still have plenty to concentrate on with BTM and burns, but we're also seeing meaningful growth in evidence beyond burns applications, across a range of complex wounds. Another sign that clinical acceptance is broadening is NovoSorb BTM showing up in academic textbooks, and this statistic excited me. In FY '26 alone, BTM appeared in 9 published textbook chapters, whereas across all the earlier years there was only 1 chapter. Next slide. So let's look at it geographically. Every region keeps delivering strong growth, with the Americas surpassing AUD 100 million for the first time. Our outlook doesn't hinge on any single growth lever. Each region presents different opportunities at differing stages of maturity. In North America, the major opportunity covers PMA approval and the RCT clinical study report, moving into outpatient care in FY '27, and deeper penetration of existing accounts and MTX. Beyond the U.S., there's still considerable runway via new products and indications. In FY '27, we'll be roughly aligning investment and commercial execution with how mature each market is, going deeper where we're established while selectively building markets that hold a quantifiable opportunity for introducing NovoSorb.
Bruce Peatey
executiveMoving to the next slide. I want to begin by reaffirming that our ambition as a growth company is still high. The leadership team's focus now is on turning that ambition into clear direction and accountable actions. Our strategy begins with the strength of what we already have: a differentiated complex wound portfolio, established clinical leadership, and a significant opportunity for deeper penetration in existing markets. The next phase is about leveraging the portfolio more deliberately to maintain strong growth in BTM, MTX and soon to come SynPath by prioritizing application opportunities where clinical need and potential commercial return are the strongest. By leveraging the platform, we commit to increase the velocity of our innovation engine. This includes next-generation products to fuel expansion in our core business and getting back to the science of our polymer technology to unlock potential new ways. Every company goes through evolutionary inflection points. PolyNovo has grown substantially over the several years. Our commercial teams are expanding. Our manufacturing output and capacity is increasing in a highly regulated market. So we plan to sharpen our focus on organizational capability and accountability during FY '27 to translate clinical leadership into sustainable long-term value. Next slide.
Bruce Peatey
executiveThe opportunity in front of us is wide. So a key responsibility for any management team is making it clear where our resources go. For FY '27, that comes down to 5 priorities: moving PMA toward approval and sharing the RCT results at the right time, bringing SynPath into the U.S. outpatient market, accelerating MTX, picking up the pace of innovation, which includes adding business development capabilities, and getting better operating leverage as we scale. Execution ties all of it together — turning the capabilities and investments we've built into commercial outcomes, sustainable growth and stronger returns. With those thoughts, I'll pass things to Jan now. The platform has proven itself, and its full potential is still ahead. Burns stay an important foundation, while complex wounds, MTX, outpatient care and other applications widen the opportunity substantially. This isn't just an aspiration. Non-burn indications are already expanding much faster. MTX is gaining traction, and multiple growth levers exist across geographies and care settings. What you should expect from the refreshed leadership team is focus and execution. Thank you. Jan, over to you.
Jan-Marcel Gielen
executiveThanks, Bruce. Moving to the next slide, please. And once more, thank you all for being on the webcast today. I'll begin with how our commercial sales performed. For the year, NovoSorb product sales came in at $138.4 million, which is 16.7% higher than last year and, in constant currency, 21.3% higher, as Bruce just noted. Measured in dollars, sales rose by $19.7 million. We finished the year with a strong June result, which included a record U.S. sales outcome. That was reinforced recently in July, when group sales for the month surpassed $13 million, setting a new record. This is a solid signal of the momentum within the business as we move into the new financial year. We saw continued growth in the U.S., where we achieved sales of $102.1 million, up 15.6% for the year. FY '27 brought significant FX headwinds, caused by a stronger Australian dollar relative to the U.S. dollar. With that in mind, U.S. sales in constant currency were in fact up 21.1%. This growth was driven by strong account acquisition, with 200 new hospital accounts added during the year, along with continued penetration of existing accounts, bringing total accounts in the U.S. to over 880 now. As for the Rest of World result, we posted sales of $36.3 million, up 20% on last year and up 21.9% in constant currency.
Jan-Marcel Gielen
executiveThere are some outstanding outcomes in several markets, with growth rates significantly exceeding 30%, and I'll point those out a little later on in the presentation. Group-wide NovoSorb MTX sales came to $12.6 million, an increase of 89.6%, with sales recorded not only in the U.S. but in Canada, Australia, New Zealand, India and Hong Kong as well. Let's go to the next slide, please. Now turning to some other highlights for the U.S. As I just noted, the U.S. delivered 21.1% sales growth in constant currency for the year. U.S. NovoSorb MTX sales reached $12.2 million, which is 92.7% higher in constant currency. Surgeon uptake of NovoSorb MTX keeps expanding and will speed up throughout the customer base as further clinical evidence is produced and disseminated. More than 330 accounts in the U.S. have now used NovoSorb MTX, twice as many as at the same point last year. At present we have 132 staff in the U.S., among them 106 on the sales team. Average sales per sales team member keep rising as we deepen penetration in existing hospitals across a broader set of indications, helped as well by the availability of an additional product, NovoSorb MTX. Because of this, productivity of the U.S. team overall has gone up, which raises operating leverage and profitability. In addition, the U.S.
Jan-Marcel Gielen
executiveOur business is still producing robust cash flows, and debtor days remain comfortably inside what we expected. Let's go to the next slide, please. Turning now to results for the Rest of World. As I noted, constant-currency sales rose 21.9% versus the prior year. We delivered some outstanding outcomes in markets that are fairly new as well as in ones that are well established. Australia in particular — our home market, which we entered several years ago — was up 33.9%, an excellent result. Ireland, up 38.3%, ranks among our strongest markets on a per capita basis. Outcomes in long-standing markets like Ireland and Australia, for example, are a solid signal of adoption by surgeons who use NovoSorb BTM, not only in large burns but across a range of indications. Hong Kong sales carried on at a strong pace, posting 49.9% growth for the year. Turkey has likewise sustained its strong growth, rising 79% for the year. India turned in a consistent growth rate, with sales growth of 52.8% for the year. In addition, after our first sales in Malaysia in June last year, we have been receiving monthly orders, with each order growing in value, and we will invest in that market by hiring 2 sales reps this quarter. We have seen comparable growth in the Czech Republic since first sales late last fiscal year.
Jan-Marcel Gielen
executiveSales outside our home market represent 26.2% of worldwide sales at this point, and we believe there are meaningful growth prospects, especially across Europe and the Middle East over the near term. Let's go to the next slide. Turning to the P&L, I'd like to begin by calling out the underlying EBITDA result for the year. Once we adjust EBITDA for significant items — namely the effect of the R&D lab fire and the unrealized forex impact from translating the balance sheet given the strength of the Australian dollar — adjusted EBITDA came in at $13.4 million, which is 50.4% higher than the prior year. Several one-off items affect the reported net profit after tax figure, and I'll walk through those now. As anticipated, BARDA revenue is lower than the prior year. The pivotal burns trial has finished, and we are completing the premarket approval submission to the FDA. Because the BARDA pivotal trial has wrapped up, trial costs have come down, and that is what accounts for the reduced R&D expense in the period. Now to gross margin. You might remember that in the first half, with inventory at comfortable levels following the build-up during FY '25, we seized the chance to move forward work on a range of tasks at our manufacturing sites ahead of the premarket approval submission and the FDA audit that will come later.
Jan-Marcel Gielen
executiveSo to achieve that, we cut production levels temporarily during the first half, and that in turn lowers the production recovery available to absorb manufacturing overhead costs. Even though we raised manufacturing output during the second half to 3.8x what the first half produced, gross margin showed only a modest gain in the second half — 89.2% versus 88.7% in the first half. For the full year, the margin came in at 89.0%. At year-end, several adjustments get booked to reflect the underutilization of the facilities that happened in the first half. Because of that, the underlying gross margin in the second half was well above 90%. Other income contains a $6.0 million insurance claim tied to the R&D lab fire. That offsets the $4.7 million asset write-off shown further down in the P&L. Employee-related costs rose 5.7%, or 4.3% once share-based payments are excluded, while headcount stayed flat at roughly 300 employees as of 30 June. Underlying corporate admin and overhead expenses were in fact 1.1% lower than the prior year once unrealized forex movement from balance sheet translation is excluded. That unrealized forex movement arises because the Australian dollar strengthened against the U.S. dollar over the period, producing an unrealized forex loss of $2.7 million for the year, versus a $2.2 million unrealized gain for the year.
Jan-Marcel Gielen
executiveThis specific cost lands in the corporate administration and overhead category within the statutory P&L. That's why it matters to strip it out and examine the underlying result. Regarding operating leverage, it's on the rise, and the bottom line is growing more responsive to sales growth — shown by the 50% lift in EBITDA once significant items are adjusted for. Next slide, please. Turning now to cash flow and the balance sheet. We closed the period holding $35.4 million in cash, which is $1.9 million higher than last year's balance of $33.5 million. Operating cash flow came to $23.1 million, a substantial improvement over the prior year's $3.1 million, driven by robust debt collections across every market. We finished building the new manufacturing facility in Port Melbourne, with CapEx payments of $12.4 million during the period. We also began reconstruction of the R&D lab and offices, making progress payments of $1.4 million, all of which insurance fully covers. A further $1.5 million of CapEx is still outstanding for machinery at the new manufacturing facility, and that gets paid in the first half. Even after funding $13.8 million in CapEx, the business generated free cash flow of $9.4 million — an important milestone achievement for the business.
Jan-Marcel Gielen
executiveTo wrap up, we finished the year with a solid balance sheet and free cash flow, and that gives us room to concentrate on more investment, push revenue growth, and — importantly — drive product innovation. Thank you. At this point I'll turn things back over to Bruce.
Bruce Peatey
executiveThanks, Jan, and I appreciate everyone being here today and for the ongoing backing you give PolyNovo. As you've already heard, we're heading into the first half with considerable momentum, a well-defined strategy and a strong dedication to getting things done. Our attention stays fixed on producing real clinical impact, expanding around the world and realizing the complete worth of the NovoSorb platform. I take great pride in everything the team has accomplished and feel sure about the opportunities that lie ahead. We're eager to share updates on how we're progressing and we thank you for being engaged with us today. So at this point I'll pass things to the operator so we can begin Q&A.
Operator
operator<<operator_script>> Our first telephone question is from Lyanne Harrison at Bank of America.
Lyanne Harrison
analystCould we begin by looking at Slide 11 and the opportunities you see for 2027? Regarding the PMA for BTM, is the submission timetable set for the close of this calendar year still in place? And what has to take place between now and that submission? Then, once it has been submitted, what do you expect the FDA review timeline to look like?
Bruce Peatey
executiveLyanne, I appreciate that question. Yes, regarding the timeline, we said earlier this year that we made a conscious choice to use the chance to review the program's scope in light of the FDA's updated guidance. We decided to move certain activities that were going to happen after submission to before submission, with the aim of delivering a fuller and more persuasive package in a single filing. It also let us get the clinical report results aligned with the 18-month period, the patient follow-ups. Everything is tracking well on that front. Once we submit, I have consistently stated that our objective is a PMA approval rather than rushing toward a PMA submission. And we believe we are well positioned for that, having worked through this review timeline. So after that filing is in, it becomes more suitable to discuss the clinical study's outcomes. At that point we are largely in the FDA's hands as they work through their process over several months, including, we expect, an inspection of the facility.
Lyanne Harrison
analystAll right, so on the FDA approval side, the expectation is maybe the middle of next calendar year — is that correct?
Bruce Peatey
executiveSo yes, months is right. And once more, we look at the FDA timeline. From what we've learned and our own experience, we're ready to collaborate with them, and it lands at roughly that 12-month point after submission.
Lyanne Harrison
analystSure. But is that quicker pace coming from the extra submissions you've been making?
Bruce Peatey
executiveThat's hard for us to pin down. What I can tell you, though, is that we'll be putting forward a very complete submission, with the work happening before we submit rather than, as originally planned, some of it taking place afterward. Personally, I feel more confident about how we'd move forward in that respect.
Lyanne Harrison
analystOkay. And then, moving on to SynPath, if I may. Could you update us on where things stand regarding that outpatient opportunity—especially on the effort to secure reimbursement, and where SynPath currently is with respect to the launch?
Bruce Peatey
executiveYes. So as we move forward, we are getting ready for commercial launch. Where reimbursement is concerned, SynPath already has a HCPCS code. So that's not something we're worried about. But as I think most people who follow this space know, the market has seen a fair amount of turbulence since the beginning of the year, as everyone adjusts to the new policies coming through CMS. So we've brought market access capabilities into the organization to help us steer through a space that's very different from the inpatient market we're in every day. So it isn't just about the product or reimbursement — it's also about whether providers feel confident that they can get paid under this new system. And with all the various movements, that turbulence is something we've been watching as we get ready to launch into the market. So commercial readiness is underway. We're ready for our commercial launch. It's going well, I would say.
Lyanne Harrison
analystAll right. So given the difficulties the market is dealing with right now, how do you see the ability to break into that market, obviously?
Bruce Peatey
executiveWe're being quite intentional about how we enter the market. We want to be certain we've got the right go-to-market strategy in place, and that covers not only the sales force but also which indications are the most clinically sensible for us to engage in and that carry a meaningful commercial opportunity as well. So what you're describing are procedures that tend to be single-episode rather than the repeated episodes you may encounter with some of those chronic wounds. We see substantial opportunity in that area, and it actually aligns very well with the momentum we have right now in the inpatient setting. The contact points are similar, the surgeons involved are similar — it's simply a different care setting.
Operator
operatorShane Storey of Canaccord Genuity has the next question.
Shane Storey
analystBruce, I believe I'll remain on the SynPath topic for just another two or three minutes. Regarding the settings involved, would it be fair of me to expect that at this stage you would likely focus on the outpatient setting — more the hospital outpatient department — instead of moving into, say, the wider private physician market?
Bruce Peatey
executiveYes, that's right, Shane. Appreciate the question. For us, it's a logical first step. As I mentioned, we already have that relationship with the surgeons at those hospitals. At present we have more than 100 reps, and they're in more and more hospitals each day. I believe the most recent count was over 800 and rising — so that makes it a logical first step. As for the indications, if you consider some of the oncology repair-type reconstruction procedures, those can reach further beyond the hospital setting. And we're examining opportunities to serve those markets over time as well. But you're correct: a logical first step is hospital outpatients.
Shane Storey
analystAnd if you consider where the evidence currently sits, what are your thoughts on what further evidence development might be suitable? I realize that is somewhat of an open question for everyone in the category, but I would just be interested to hear your perspective on it.
Bruce Peatey
executiveYeah, that's correct. And going forward, the evidence requirements also have to be set out. Across multiple indications, we keep accumulating more and more evidence. As I said during the presentation, whether it's in the chronic wound space or in the more acute setting, we're seeing evidence that applies to this space. But we're also aware that if more specific evidence needs to be generated, we're open to that. What I can tell you is that even the strategy of moving into procedures that better fit our products' capabilities and advantages — I think we're well positioned with the evidence we have.
Shane Storey
analystOne last question, and it's for Jan. Jan, I appreciate your walking us through the different gross margin movements across the half. I guess what I'm really asking is whether any of those mechanics could reverse in FY '27 — I suppose particularly as new facilities come online — and how you'd expect that overhead to hit the margin over the next year or 2?
Jan-Marcel Gielen
executiveRight, of course. At present, that new facility can't be used. As a result, it isn't affecting margin. And we won't be shifting over to the new facility until roughly March of next year, and the move will probably begin with MTX. We're currently in the process of validating machines and so on. That's the case even though the facility has been built. So we won't see that effect until about the fourth quarter. Before I get into that, I'll mention how margin is tracking, and we've now returned to normal levels from our existing facilities. So in July, gross margin came in at just under 95%, and that's roughly what we're accustomed to. And that results from strong sales that actually beat budget in July. We had $13 million in sales for the group, which was a record, but we also met budget or target for our production output in July. So when that occurs, you get a 95% gross margin. So with all of that continuing as planned, and we meet our targets from now until, say, December, our first half, our gross margins will fall in that 90% to 95% range. Once the new facility comes on, it will have a 1% to 1.5% impact on gross margin when it's up and running, but our sales will also be a lot higher than they are now.
Jan-Marcel Gielen
executiveSo that's something you need to factor in. Still, on the whole, we're well positioned when it comes to leveraging that new facility, and we're eager to get it up and running at some point in the next calendar year.
Operator
operator<<operator_script>> The following question is from Scott Power of Morgans Financial.
Scott Power
analystLet me ask a quick question about a few of the other research efforts you have underway. You brought up SynPath and its launch, but I was hoping you could offer some commentary on hernia repair and a few of the areas you're focused on there. And I suppose the second part of that is, with that R&D spend declining in FY '26, what percentage of sales should we anticipate going forward?
Bruce Peatey
executiveAll right, thanks, Scott. On the innovation pipeline broadly, I believe you remember that at the half year I mentioned we needed to restore some speed in that pipeline. One of the earliest moves toward that is appointing a Chief Scientific Officer, and that's what we did. It's great to have Marthe D'Ombrain on the team now. Two months in, I can genuinely see that the rigor and discipline around pipeline visibility and how we approach it are clearly getting better. So we have that in place. Within that mix, as you said, we have several products — hernia and breast recon, as we discussed earlier — and we also have products in that pipeline going through a very deliberate prioritization process. So we will have — my focus is on making sure that speed returns to the innovation pipeline and on being able to make the tough calls. Unless there is a clinical differentiator, unless there is also a very strong commercial need for the product, we will make those tough calls on whether they remain in the pipeline or not. And I look forward to sharing more on that once Marthe has a bit more time under her belt.
Bruce Peatey
executiveI'd say I'm quite pleased too with the way she's going about it—beginning to incorporate the voice of the customer, including clinician groups, and over time she intends to set up more formal forums for scientific advisory, with that effort starting during this calendar year. So by and large, what matters is confirming we've got a disciplined process in place for our innovation pipeline so we can restore that velocity within our system. On the spend question, I'll have Jan address that. Still, I believe that as we move away from the heavy lifting tied to PMA preparation, we'll see a greater share of the investment flowing into R&D to help drive this gain in velocity.
Jan-Marcel Gielen
executiveJust to build on that, looking at R&D spending as a share of sales, it should come in at roughly 5% of sales next year, and that figure leaves out the R&D costs that historically were parked in that line within the statutory P&L. All of that has now finished. So — and picking up on Bruce's point, though, Marthe, our new CSO, has been in the job only a couple of months, and there — she is getting her arms around things. And we do want to put more money into R&D. We do want new products coming out as well as line extensions. But so expect it to rise, though next year it will be near roughly 5% of sales.
Scott Power
analystRight, okay. And if I could, a second question. You mentioned several regions in Rest of World that have performed very strongly. Are there any that might be underperforming and due for review?
Bruce Peatey
executiveI think, just to chime in on that point and the questions about the rest of the world, it really comes back to what we've learned, especially regarding how those markets are evolving. We talk about markets sitting at different levels of maturity. And again, as the mix shifts between the large complex burns and the other complex wound applications, until that mix evolves, we'll see some variability across those markets. That's why I highlighted the deliberate approach for at least 2027, FY '27, which is to go deeper in certain high-potential markets rather than placing more emphasis on entering more markets. So we definitely believe there's potential, particularly in some European markets, to go a bit deeper and build up the momentum we've seen in some of our more established markets like Australia, which is performing extremely well as one of our most mature markets, and you can see how that mix is changing in the U.S. I'd like to see that happen more in some of the European markets. And Jan, I don't know if you have anything to add?
Jan-Marcel Gielen
executiveThere isn’t much else I’d add, though we’ve delivered some truly strong results. We understand what strong performance looks like, and we know the route to achieving it in specific markets. <<inaudible>> play a key role in backing distributors. So we’ll keep doing that. And for anyone who was, say, falling away, we’ve been able to bring them back. Still, opportunities are plentiful. In the Middle East too, we see openings, since we’ve had product entering that region ever since the war happened and all the activity has continued. Regrettable events have taken place there. So that’s an additional opportunity we’re going to examine as well.
Operator
operatorOur following question is from Andrew Paine at CLSA.
Andrew Paine
analystSo, during the trading update, you said June had hit record sales levels. It would help if you could put a number on those sales and perhaps share some insight into how sales were trending as FY '27 got underway.
Jan-Marcel Gielen
executiveSure, I'm glad to step in on that, Bruce. Yes, as we already noted, July actually turned out to be a record month for the group. So we ended up posting sales above $13 million. The U.S. came through again, which is great. That's a very encouraging signal for how we expect the quarter to finish. So yes, things haven't fallen off a cliff. They've gone the other way, which is a really good indication.
Andrew Paine
analystI may have overlooked that point earlier. Then, regarding the operating expenses where you're providing some leverage through '26 — I'm particularly curious about employee-related costs, since obviously there are FX movements involved there. Could you offer any guidance on a constant currency basis for employee-related expenses as we look ahead to '27?
Jan-Marcel Gielen
executiveI don't have that in front of me at the moment, right now. But when it comes to volatility, we really hope we won't experience the kind of swings we saw this year and the hit they took on the P&L, especially revenue. On the cost side overall, the leverage is clearly showing up. If you look at corporate admin and overhead costs, they're 1% lower than the prior year. We're extracting much more productivity from the whole group, especially across all our sales and marketing subsidiaries. So average sales per rep in the U.S. keeps climbing, driving greater profitability. We're seeing the same thing in the U.K. and Australia and so on. And that will come through even more strongly this year. I'd say the EBITDA, or the profitability line, is now highly sensitive to sales growth. You can see that in underlying EBITDA rising by 50%. We did have that impact, but we're off to a good start with record sales, a gross margin of 95% in July, and we'll work to make sure that carries on through this first half.
Andrew Paine
analystThanks, that’s helpful. And just one final item: when we look at your adjusted EBITDA figure for significant items, clearly the asset write-off is there. Regarding the insurance — the interim insurance claim — where does that show up in the P&L?
Jan-Marcel Gielen
executiveWe're positioned in other income. The net effect is a $1.1 million gain to the bottom line, but obviously we've added that back by adjusting for significant items. So the underlying result leaves out any insurance impact as well as the asset write-off impact.
Operator
operatorThat brings an end to the questions we have from callers. At this point, I'll return the conference to your speakers so they can take the questions submitted through the webcast.
Jan-Marcel Gielen
executiveThanks, Bruce. We have several questions that have come in. First is India. What's the plan there? Is it at break-even yet? Will we keep putting money into that market?
Bruce Peatey
executiveAbsolutely, that's a good question. We're really pleased with how things are going in India. That team is showing strong growth once more. More significantly, though, the fundamentals underpinning that business are extremely solid. The team has established a business that is dependable, compliant, and solid, and it keeps expanding — especially when I consider leading indicators, such as the effort put in over multiple years to secure contracts in India. That process tends to take a while. Two years later, we're beginning to win tenders that have only recently been issued. So it took considerable effort to reach this point. We have that pipeline of tenders and contracts lined up, and we're watching them convert. As a result, we're now present in many more hospitals, including several of the major AIIMS hospitals across India and the biggest burn center in Asia, located in Delhi. So growth has been very strong. Regarding profitability, we expect that during this financial year — we're really targeting the second quarter to ensure the business is profitable. Yet we keep growing, applying discipline on the cost side so that returns on that investment begin to show before we move to the next stage.
Bruce Peatey
executiveStill, every indicator points in a favorable direction. Jan, I’m not sure whether you’d like to add anything at this point?
Jan-Marcel Gielen
executiveYes, that's precisely it. So it will keep expanding organically and should reach break-even before Christmas. And their growth is substantial. They have many cases that they keep treating. The increase has truly been remarkable when it comes to patient numbers, especially relative to other markets, but we are gaining ground on the larger burns, and that simply requires time. Turning to another question now, Bruce, regarding competition within the U.S., and specifically about Avita and its synthetic products plus other synthetic rivals that might be emerging. What are we observing in the U.S. market? And what is our response?
Bruce Peatey
executiveSo yeah, there is some noise in this space, a bit of it. And I believe that ties back as well to what we are observing in the outpatient segment, where several players in the market have faced turbulence caused by the policy changes. In inpatients, we are seeing somewhat more activity. But I think it matters that we ground ourselves in what BTM, MTX, and the NovoSorb portfolio actually accomplish in the inpatient setting. Namely, those large, complex cases that BTM was designed to improve patient outcomes in. Those results are well documented at this point, as we see increasing evidence, and the experiences clinicians report are quite compelling. So we might see some activity in those lower burn spaces, where faster graft and other length of stay criteria are being discussed. We do have options in that space. But once again, it is the larger wounds and the more complex cases where we really shine. In those other areas, there is some trialing going on, again, but we are seeing more and more that clinicians cannot forget the great outcomes they have had with our products, and we are seeing that come back. And that shows in June being a record sales month for the U.S., with July backing it up.
Bruce Peatey
executiveWe are absolutely ready for the challenge, and we have a product we believe can hold its own against any competitor.
Jan-Marcel Gielen
executiveThanks, Bruce. On that point, there's a question from David at E&P, Evans & Partners. He notes the FX effect in the second half and the burn seasonality affecting second-half sales, even with 5% sequential growth in the U.S. So what puts the business back on a path toward roughly a 20% growth rate? And how are we progressing on penetrating existing accounts plus the 200 accounts added during the year? Really, the question is how we speed up growth in the commercial markets.
Bruce Peatey
executiveI think the priorities here are pretty clear. As I laid out, we have momentum in that large burn space, and until recently the main focus there was on winning additional accounts. We're present in most of the large burn accounts in the U.S., especially when we treat the U.S. as the driver. And we have penetration into those accounts. But that's not the whole story. It's also the credibility we've built by being in those accounts, which you can see is driving adoption of the product, whether that's BTM, MTX or BTM and MTX in those complex wound cases. So that's where we see it. And you can see the growth of complex wound applications outside those large accounts growing over 50% on a 3-year CAGR. I think that gives us a lot of confidence that we have a runway for growth. And again, outside the U.S., with some more focused activity around those larger markets where we can improve penetration, I think we can see that happening as well.
Jan-Marcel Gielen
executiveThanks, Bruce. There are a fair number of questions about the R&D pipeline, so this seems like a good moment to say where things stand. And then, just to reinforce what you mentioned earlier, Bruce, regarding our investment in that area and how the pipeline will develop — plus anything you can share on that front — to give shareholders reassurance that we're working on it.
Bruce Peatey
executiveYes, certainly. As we said, additional resources will be directed into that program over the course of FY '27, now that we're beginning to wind down some of the PMA activity. But we're bringing — I have to say this — we're bringing more discipline to how we make innovation and portfolio decisions. And that matters so that we can decide whether to accelerate, postpone, or even terminate projects, in order to get the output we're aiming for. So there's considerable discussion about hernia and breast recon. Those are certainly under consideration as we determine the focus areas for our portfolio. We also have products in the pipeline that speak strongly to our strategic pillar of scaling the core business, which we intend to advance and keep fueling growth in our complex wound application business. Beyond that, making sure work is underway on the platform's potential. As I say, and from what I've learned, we have this beautiful polymer, which is a gift to our business. And then in recent years, understandably, we've focused a great deal on growing the U.S.
Bruce Peatey
executiveAnd we’re making sure we back BTM expansion, with MTX entering the market and now SynPath also entering the market. We’ll direct part of our innovation focus and decision-making toward figuring out what this platform can do to create the next growth engine for the business beyond the core business. I’m genuinely excited about that — that we now have both the opportunity and the capabilities within the business to manage those well and sustain momentum in the core business.
Jan-Marcel Gielen
executiveThanks, Bruce. Appreciate it. So, one question here mentions it's good to see textbook publications that reference our products and so on. Which specific trials does PNV currently have running? That way, fresh regulatory approval filings can actually be submitted with scientific backing for new indications. So, are any RCTs in progress? Perhaps this is also a chance to discuss the IQVIA studies as well as the health economics work and the free flap versus BTM comparison in the U.K. that we're carrying out — but any evidence at all.
Bruce Peatey
executiveThat's a really valid observation. So we've got quite a few investigator-initiated trials in progress across various applications, and we're glad to back them. I think returning to the RCT tied to the clinical trial, such as the PMA application, is going to be a genuine standout for me and will deliver benefits that reach well past the PMA application itself. As I mentioned, it's the biggest study of its type, the first for a synthetic, and nothing comparable has been conducted in this area for decades. So ensuring we build as much awareness as possible around those results once they can be shared is going to be a crucial component. But you raise a key point there, Jan. Health economics plays such a vital role in fueling growth within medical technology. So it isn't solely about clinical performance — that clinical performance also needs to align with willingness and ability to pay, and demonstrating the economic advantages to some of our key stakeholders. So in parallel with this study, there's health economics work under way in collaboration with IQVIA that will be capable of demonstrating the economic benefit of using BTM compared with the current standard of care. That's one.
Bruce Peatey
executiveAlso, as Jan said, there's a second health economics arm examining that — the economics of free flap, which is the procedure currently used for some of the bigger oncology surgical reconstructions — and seeing how our products compare with that standard of care. So that's really important. And I'd describe it as the third arm of this. You've got your innovation arm with R&D, you've got your sales and marketing commercialization arm, but market access — bringing that skill and capability into our business — truly completes that flywheel of growth. And I'm eager to see all of these elements come to market.
Jan-Marcel Gielen
executiveThanks. Appreciate that, Bruce. And following on from that, here's a good question. Could you remind us what PMA approval might mean for PolyNovo, both on the commercial side and when it comes to clinical evidence around the world?
Bruce Peatey
executiveYes. First, I'd say credibility. Passing through what truly is the top tier of clinical research and then securing PMA approval lends real credibility to the BTM platform, and that's a genuine advantage. Beyond that, it assists us with reimbursement, since it provides the capacity to seek reimbursement. I want to remind everybody that this is such a crucial point. What we've achieved in the U.S. has come up against an incumbent technology that already holds reimbursement and already has that approval. Until the PMA approval, we lack the indication for deep burns. So the team doesn't promote it. This expansion is led by clinicians. For me, that's the strongest message one could ever convey regarding BTM. The fact that this product, via clinician and peer-to-peer education and the sharing of their experiences, has expanded to the degree it has is rather distinctive. That gives me confidence, beyond the PMA approval, that we can carry on that good work, actively promote, and actively defend the product. And I believe the third element is that outside the U.S., that credibility then assists us in entering markets such as the ones we've mentioned in Asia, like Japan, possibly later on, China — that kind of evidence helps.
Bruce Peatey
executiveYou will still likely run into requirements for local evidence at times, but from a registration standpoint that certainly boosts credibility. And beyond that, when you go into European markets, say, it genuinely lets our portfolio carry a bit of swagger.
Jan-Marcel Gielen
executiveThank you, Bruce. You might have already addressed this in that earlier question—I've been occupied going through questions here. There are questions about entering Japan and China, and a remark—I believe you held talks with the PMDA in Japan. Could you give us the most recent update?
Bruce Peatey
executiveRight. Yeah, absolutely. So in Japan, I had the chance to meet with the distribution partner we work with there. Commercial readiness is moving forward as far as it can ahead of registration. To give you a sense, I attended a burns conference in Tokyo that was conducted entirely in Japanese — I relied on translation, but I could follow what was being said. The enthusiasm there is definitely real. The other part of the equation isn't just registration, though the clinical study will support that effort — it's reimbursement as well. So it's about bringing all those elements together to confirm this market will deliver added sustainable growth for us over the long term — tying those pieces together. That said, what I see as the gating item right now is reaching the far side of that PMA approval and being able to share that clinical study.
Jan-Marcel Gielen
executiveThanks, Bruce. I'll let you take a breather for a second. There's a question here, and I can handle this one. Could you please elaborate on that comment about augmenting the manufacturing footprint? What we really mean by that is making the transition to our new facility, which we're aiming to do in March next year. Then it will be a phased approach as we exit out of the other 2 facilities that we currently have in place. And one of those older facilities will be retained as a redundant facility, or a backup, if you like, which is a good thing to have. But that's really what that comment means. Just scrolling through, just give me a moment. A question again about the DFU outpatient market in the U.S. Are we going to be conducting any trials? And what evidence do we have that we could use to submit to CMS right now?
Bruce Peatey
executiveYes. So CMS has created a chance for additional evidence submissions, and we intend to use it by providing data from various parts of the world. We possess certain local evidence that is quite compelling regarding BTM in chronic wounds. So we'll ensure those specifics can be shared at the right time, and that will be included in the package. In one sense it's not perfect, since U.S. local data would likely be favored, as is the case in most countries, but this evidence is so persuasive. We want to make certain it can be part of it. So that's a key element. What else was the question, Jan?
Jan-Marcel Gielen
executiveYeah, I think it was basically just about what other — what are we able to submit to the CMS? And is there any specific RCT trial for DFU that we have planned?
Bruce Peatey
executiveYes. I think what I really want to convey about DFU and VLU, and those chronic wounds too, is that although we're picking up some quite persuasive real-world evidence as we go, it's key to understand that beyond the inpatient environment there are several considerations — reimbursement being one, but also physician — sorry, provider economics, that kind of thing as well. And with those chronic wounds, one issue is that they lean toward repeated application, which isn't what our product was built for. Ours is more about high acuity: there's a surgical procedure, you apply the product, and it does its job. So we're making sure all those considerations are in alignment as we examine that segment of the market. That segment, and our patients within it, is the one experiencing the greatest amount of flux. And so we have opportunities in areas that fit very well with our customer base, fit very well with what our product is capable of, and hold substantial market potential that we can pursue by focusing on those single episodic cases. So that's our starting point.
Jan-Marcel Gielen
executiveThanks, Bruce. This one will be our final question. We're nearing the hour mark, and actually we've pretty much covered all of them. If any are left over, we'll follow up by e-mail once the call ends. It's an important question. It also gives us a chance to discuss how we really mitigate risks as well. So here we have it: what are the biggest risks you see to hitting your plan over the next couple of years?
Bruce Peatey
executiveAs I mentioned, we have a platform that's proven and that we know works. The product doesn't concern me. Honestly, competition doesn't concern me either. Execution is our main focus. And we're instilling that discipline throughout the organization so that operating mechanisms exist from leadership down through every level, ensuring we deliver on our commitments. That matters greatly to me. It always has, and it always will. So we're establishing those forums, those operating mechanisms, to guarantee execution. Since I joined in December, I've been very pleased with how the organization has progressed. I believe we now have a leadership team where we've brought in added capabilities, paired with substantial institutional knowledge from leaders who've been with the organization for some time. This team is powerful. We'll keep getting stronger, and with the rhythm now in place, we'll stay focused on priorities and deliver what we say we will. I'm looking forward to the year ahead as we update on more of these milestones being completed.
Jan-Marcel Gielen
executiveAlright, thanks, Bruce. I believe that's where we'll stop for this hour. And I suppose thanks to all of you for joining the call, and I'll turn it back over to you, Bruce, for any closing comments.
Bruce Peatey
executiveYes, just to wrap things up, I want to thank all of you for being here. I appreciate the time you've given us. I hope the information shared has been useful to you. Our plan is to keep communicating with the market as appropriate whenever we have significant updates, so keep an eye out for those. I believe we've turned the corner in terms of starting the year strongly, ending the year strongly, and getting off to a strong start in July. I'd aim to carry that momentum through the remainder of FY '27 as we begin these important milestones — an exciting year lies ahead.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete PolyNovo Limited transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to PolyNovo Limited earnings transcripts and 131,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in PolyNovo Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.